A Phase I Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors.

Trial Profile

A Phase I Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2018

At a glance

  • Drugs Pegzilarginase (Primary)
  • Indications Malignant melanoma; Small cell lung cancer; Solid tumours; Uveal melanoma
  • Focus Adverse reactions; First in man
  • Sponsors Aeglea Biotherapeutics
  • Most Recent Events

    • 05 Apr 2018 According to an Aeglea Biotherapeutics media release, Phase 1 dose escalation data from this will be presented at the 2018 Annual Meeting of the American Association for Cancer Research (AACR) (April 2018).
    • 08 Mar 2018 According to an Aeglea Biotherapeutics media release, company announced the dosing of the first uveal and cutaneous melanoma patients with pegzilarginase (AEB1102) in open-label expansion cohort and expect to report topline data in the fourth quarter of this year.
    • 18 Jan 2018 According to an Aeglea Biotherapeutics media release, dose escalation has been completed in this trial and the company plans to initiate Phase 1b expansion arms of the advanced solid tumor trial in small cell lung cancer (SCLC), uveal melanoma and cutaneous melanoma in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top